Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ: BEAM )

32.40 +3.79 (+13.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Analyst Ratings for Beam Therapeutics
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
5 Top Stocks for February
These growth stocks have more room to run. 
Via The Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
These beaten-down stocks could be poised for major rebounds. 
Via The Motley Fool
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
Aggressive investors should check out these stocks. 
Via The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
Making money that spans generations requires thinking big. 
Via The Motley Fool
4 Analysts Have This to Say About Beam Therapeutics
Via Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know
Via Benzinga
Beam Therapeutics's Return On Capital Employed Insights
Via Benzinga
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
3 Under-the-Radar Biotech Stocks to Buy in 2022
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy
Via Benzinga
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close... 
Via Benzinga
7 ‘Next Big Things’ for Investors to Buy for 2023
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown. 
Via InvestorPlace
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts 
From Beam Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
Via Benzinga
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via GlobeNewswire
A Sitcom Character Inspired This Investor
Plus, a look at the "Buffett premium" that investors give to Berkshire Hathaway stock. 
Via The Motley Fool
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States 
From Beam Therapeutics
Via GlobeNewswire
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.